Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Omeprazole and Sodium bicarbonate capsules, 20mg/1100mg and 40mg/1100mg, a therapeutic equivalent generic version of ZEGERID® (omeprazole/sodium bicarbonate) capsules in the United States market, having been 
approved by the U.S. Food & Drug Administration (USFDA).
The Zegerid brand and generic had U.S. sales of approximately $306.7 million MAT for the most recent twelve months ending in May 2016 according to IMS Health.
Dr. Reddy’s Omeprazole and sodium bicarbonate capsules 20 mg/1100 mg and 40 mg/1100 mg are available in bottle count size of 30.
Zegerid is a registered trademark of Santarus, Inc. a wholly owned subsidiary of Salix Pharmaceuticals, Inc.
